NewsRoom Articles - Page 12 of 37

MondayJul 24, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science

The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1% The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research…

FridayJul 21, 2023 9:00 am

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it aims to show improves on standard of care chemotherapy agent Lomustine’s approach to treating GBM Berubicin is a novel anthracycline that is practically unique in its ability to cross the blood-brain barrier to directly target…

ThursdayJul 20, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities

Lexaria is a global innovator in drug delivery platforms with an expanding portfolio of patents that currently stands at 34 granted patents and many patents pending worldwide These patents pertain to the company’s method of improving bioavailability and taste as well as the use of DehydraTECH(TM) as a delivery platform for a wide variety of active pharmaceutical ingredients (“APIs”) The company has, since June 2015, simultaneously filed the US utility patent application and an international patent application under the Patent Cooperation Treaty (“PCT”) procedure, both through the USPTO The PCT procedure has made the process of initiating international patent applications…

TuesdayJul 18, 2023 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Accelerates Intelligent Lidar Solutions Critical to Vehicle Safety and Road Management

Cepton advances lidar technology that integrates into traffic systems, intersections, and ADAS-powered vehicles to improve passenger and pedestrian safety Through partnerships with leading global OEMs, CPTN enables ADAS mass-market commercialization with ultra-compact, high-performance, and cost-effective lidar solutions CPTN’s Helius(R) Smart Lidar System was recently deployed in government-funded pedestrian safety projects in Texas and Utah Other applications of CPTN's lidar technology include airport terminal monitoring, security systems, crowd analytics, railway obstacle detection, e-tolling, and traffic management Lidar - a combination of the words “light detection and ranging” – is a sensing technology that sends out laser pulses and measures the time…

FridayJul 14, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11% Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending across several categories of fat-soluble active molecules and drugs The company operates through four separate subsidiaries to explore the potential and options for the use of DehydraTECH in respective industries Bioavailability is the ability of…

TuesdayJul 11, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023 The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations Lexaria looks to build on the momentum gathered so far, and its management is…

MondayJul 10, 2023 10:30 am

D-Wave Quantum Inc. (NYSE: QBTS) Technology Ready to Answer Call of Proposed Legislation for Near-Term Quantum Applications to Solve Optimization Problems

Legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing – some within 24 months or less for developing and deploying demos, proofs of concepts, and pilots Global government spending on quantum application development is expected to reach $36 billion during 2023 D-Wave offers quantum solutions to help government and public sector develop applications that can solve important optimization problems Recent legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing applications to solve complex public sector optimization problems, which could include electrical grid resilience, optimization…

MondayJul 10, 2023 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

ThursdayJul 06, 2023 9:00 am

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3 Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023 Genprex is combining its lead product candidate, REQORSA, with…

WednesdayJul 05, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Contract Renewal Indicates Company’s Success in Supporting International Transports

Freight Technologies (aka Fr8Tech) has developed a technology solution that uses machine learning and artificial intelligence (“AI”) to help shipping and freighting companies optimize product transports and avoid costly errors Fr8Tech recently announced that one of its top clients, multinational insulation manufacturing company K-FLEX de México SA de CV, renewed its contract for using Fr8Tech’s core tech solution, Fr8App K-FLEX cited Fr8App’s benefits to the company during the difficult COVID-19 pandemic period and beyond as K-FLEX expanded its operations and approaches $1 billion in annual revenues Fr8Tech is continuing to expand its technology frontiers with the establishment of a dedicated…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717